Galapagos Logo
BE0003818359
A0EAT9
GLPG.AS

Galapagos

Prognose

Køb
  3
Behold
  11
Sælg
  2

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Galapagos records 91% drop in revenue and launches strategic realignment

    Galapagos reported a 91.3% decline in revenue for Q1 2026 to €6.5 million, primarily due to the loss of income from the agreement with Gilead. Despite the revenue shock, the company posted a net profit of €14.5 million, driven by positive currency effects and financial results. Management announced a comprehensive transformation including a renaming to Lakefront Biotherapeutics, a focus on innovative therapies such as Gamgertamig, and consideration of a share buyback as part of a new Gilead agreement. For 2026, Galapagos expects high expenses (including a prepayment to Gilead and costs related to the acquisition of Ouro Medicines) and forecasts year-end cash of between €1.975 billion and €2.05 billion. » Mere på de.investing.com


  • RBC cuts Galapagos NV price target to $28, keeps Sector Perform ahead of Q1

    RBC Capital Markets reduced its price target for Galapagos NV from $33 to $28 while maintaining a Sector Perform rating, citing seasonal pressures including reimbursement resets, gross-to-net dynamics, fewer selling days and potential weather-related disruptions. The bank noted that rising M&A activity and clearer drug-pricing expectations could help offset near-term volatility. Separately, Galapagos and Gilead agreed a binding framework related to Gilead’s acquisition of Ouro Medicines that expands collaboration rights and includes funding and operational arrangements. » Mere på finance.yahoo.com


  • Galapagos signs agreement with Gilead on Ouro Medicines assets

    Galapagos reached a binding agreement with Gilead tied to Gilead’s acquisition of Ouro Medicines, obtaining licenses to key IP, gamgertamig (a BCMAxCD3 T cell engager) and additional preclinical programs, plus related facilities and staff. The deal makes Galapagos responsible for early-stage development while later-stage costs and global commercialization (outside certain territories) will be shared with Gilead; Galapagos can receive milestone payments and tiered royalties of 20–23% on net sales. The company can independently deploy at least $500M of cash, including up to $150M for potential share buybacks. Gamgertamig has FDA Fast Track and Orphan Drug designations for AIHA and ITP and may enter registrational studies as early as 2027. Galapagos also proposed appointing Gino Santini as non-executive independent director and future chair, subject to shareholder approval. » Mere på finance.yahoo.com


  • Galapagos and Gilead collaborate on Gamgertamig, unlock $500M and target 2027 registrational trials

    Galapagos struck a binding collaboration with Gilead on BCMA x CD3 T‑cell engager Gamgertamig, with the companies splitting an upfront payment and milestone payments (including references to ~$1.675 billion and up to $500 million) and Galapagos eligible for up to $100 million in development milestones. The deal amends the legacy OLCA and unlocks an additional $500 million of Galapagos cash (including up to $150 million potentially available for return of capital); Gilead will hold commercialization rights outside Greater China while Galapagos gets 20%–23% royalties. Gamgertamig is in phase 1b (over 60 autoimmune patients treated, >160 across all trials), has Fast Track and Orphan designations for hemolytic anemia and ITP, and could enter registrational studies as early as 2027. Galapagos will fund development through initiation of registrational studies, after which costs are shared, and management says the transaction preserves strategic flexibility and leaves the majority of cash available for other opportunities. » Mere på finance.yahoo.com


  • Galapagos exits cell therapy, shifts to business development with ~€3bn cash

    Galapagos is winding down its cell therapy program and refocusing on business development in inflammation & immunology and oncology, backed by a refreshed leadership team and board. The company ended 2025 with about €2.998 billion in cash after recognizing €1.069 billion of deferred income tied to Gilead and taking ~€399.8 million of wind‑down and restructuring charges. TYK2 inhibitor GLPG3667 showed positive Phase 2 topline results in dermatomyositis and SLE, but Galapagos says it lacks full Phase 3 infrastructure and is seeking partners to advance the program. Management expects the cell therapy wind‑down to be largely complete by Q3 2026, anticipates one‑time restructuring cash costs of €125–175 million in 2026, and aims to be cash‑flow neutral to positive by year‑end 2026. » Mere på finance.yahoo.com

Virksomhedstal

I det seneste kvartal havde Galapagos en omsætning på 7,42 mio. € og et nettoresultat på -2,61 mio. €

(EUR) september 2026
YoY
Omsætning 7,42 mio. 89,58 %
Bruttofortjeneste 3,82 mio. 93,67 %
Nettoresultat -2,61 mio. 98,71 %
EBITDA -39,84 mio. 78,98 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
2,11 mia. €
Antal aktier
65,9 mio.
Højeste/laveste i 52 uger
31,99 € - 23,88 €
Udbytte Nej
Beta
0,11
P/E (PE Ratio)
4,18
PEG (PEG Ratio)
-0,11
K/I (PB Ratio)
0,63
P/S (PS Ratio)
1,94

Virksomhedsprofil

Galapagos NV er et integreret biofarmaceutisk selskab, der beskæftiger sig med opdagelse, udvikling og kommercialisering af forskellige lægemidler til områder med stort, uopfyldt medicinsk behov. Selskabets pipeline-produkter omfatter filgotinib, en JAK1-hæmmer, som er i forskellige faser af kliniske forsøg til behandling af reumatoid artritis, Crohns sygdom, colitis ulcerosa, småtarms-CD, fistulerende CD, ankyloserende spondylitis, psoriasisartritis og uveitis. Selskabets pipeline-produkter omfatter også GLPG1972, som har gennemført et fase 2b-forsøg til behandling af osteoartrose; Toledo-molekyler, herunder GLPG3970, GLPG4399 og GLPG4876 til inflammation; samt GLPG4716 og ziritaxestat til behandling af idiopatisk lungefibrose. Derudover omfatter selskabets øvrige pipeline-produkter GLPG2737, en cystic fibrosis transmembrane conductance regulator, der er i fase 2-kliniske forsøg til behandling af patienter med autosomal dominant polycystisk nyresygdom; og GLPG0555, en JAK1-hæmmer, der er i fase 1b til behandling af patienter med osteoartrose. Selskabet har samarbejdsaftaler med Gilead Sciences, Inc.; AbbVie S.à r.l.; og Novartis Pharma AG. Galapagos NV blev stiftet i 1999 og har hovedkontor i Mechelen, Belgien.

Navn
Galapagos
CEO
Henry Gosebruch
Hjemsted Mechelen, bu
Belgien
Websted
Sektor
Sundhed
Branche
Bioteknologi
Børsnotering
06.05.2005
Medarbejdere 452

Tickersymboler

Børs Symbol
Euronext
GLPG.AS
Pnk
GLPGF
Amsterdam
GLPG.AS
Frankfurt
GXE.F
Düsseldorf
GXE.DU
London
0JXZ.L
München
GXE.MU
Wien
GLPG.VI
🍪

Parqet  bruger cookies. Læs mere